Squadron Capital Management LLC 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Squadron Capital Management LLC disclosed 30 US equity positions worth $250.0m in its Q1 2026 13F filing. The largest position was RLMD at 23.6% of the reported book, followed by COGT and 4XC1.
What did Squadron Capital Management LLC own in Q1 2026? Top 30 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 23.6% | $59.0m | 8,474,571 | – | |
| 2 | COGT COGENT BIOSCIENCES INC | Healthcare | 12.1% | $30.3m | 787,492 | – | |
| 3 | 4XC1 KALVISTA PHARMACEUTICALS INC | 7.9% | $19.8m | 985,100 | – | ||
| 4 | KOD KODIAK SCIENCES INC | Healthcare | 5.8% | $14.5m | 380,000 | – | |
| 5 | ABVX ABIVAX SA | Healthcare | 5.8% | $14.5m | 130,000 | – | |
| 6 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 4.4% | $11.0m | 350,000 | – | |
| 7 | NKTR NEKTAR THERAPEUTICS | Healthcare | 3.6% | $9.0m | 125,000 | – | |
| 8 | ANL ADLAI NORTYE LTD | 3.5% | $8.8m | 1,265,231 | – | ||
| 9 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 3.4% | $8.5m | 3,631,000 | – | |
| 10 | MAZE MAZE THERAPEUTICS INC | Healthcare | 3.1% | $7.7m | 257,500 | – | |
| 11 | SCYX SCYNEXIS INC | 2.8% | $7.0m | 7,608,695 | – | ||
| 12 | RLAY RELAY THERAPEUTICS INC | Healthcare | 2.7% | $6.7m | 672,500 | – | |
| 13 | CCCC C4 THERAPEUTICS INC | Healthcare | 2.4% | $5.9m | 2,250,000 | – | |
| 14 | IKT INHIBIKASE THERAPEUTICS INC | 2.4% | $5.9m | 3,500,000 | – | ||
| 15 | PALI PALISADE BIO INC | Healthcare | 2.1% | $5.2m | 3,000,000 | – | |
| 16 | EPRX EUPRAXIA PHARMACEUTICALS INC | 2.0% | $4.9m | 680,000 | – | ||
| 17 | GHRS GH RESEARCH PLC | Healthcare | 1.8% | $4.6m | 325,000 | – | |
| 18 | PROMIS NEUROSCIENCES INC | 1.7% | $4.1m | 324,977 | – | ||
| 19 | LPCN LIPOCINE INC NEW | 1.4% | $3.6m | 450,000 | – | ||
| 20 | IVA INVENTIVA SA | 1.2% | $3.0m | 535,000 | – | ||
| 21 | ALXO ALX ONCOLOGY HLDGS INC | Healthcare | 1.2% | $2.9m | 1,460,000 | – | |
| 22 | CNTX CONTEXT THERAPEUTICS INC | 1.2% | $2.9m | 1,100,000 | – | ||
| 23 | NXTC NEXTCURE INC | 1.1% | $2.8m | 265,000 | – | ||
| 24 | SOL-GEL TECHNOLOGIES LTD | 1.0% | $2.5m | 31,000 | – | ||
| 25 | KTTA PASITHEA THERAPEUTICS CORP | 0.6% | $1.6m | 2,100,000 | – | ||
| 26 | TRAW TRAWS PHARMA INC | 0.4% | $936.4k | 511,714 | – | ||
| 27 | TXMD THERAPEUTICSMD INC | 0.3% | $849.2k | 420,421 | – | ||
| 28 | SPRB SPRUCE BIOSCIENCES INC | 0.3% | $797.3k | 12,200 | – | ||
| 29 | HOWL WEREWOLF THERAPEUTICS INC | 0.2% | $469.2k | 563,535 | – | ||
| 30 | NEUP NEUPHORIA THERAPEUTICS INC | 0.1% | $312.3k | 76,728 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.